Azathioprine, UV light, and skin cancer in organ transplant patients - Do we have an answer?

Nephrology Dialysis Transplantation

Volumn 22, Issue 4, 2007, Pages 1027-1029

  Ulrich, Claas ^a   Stockfleth, Eggert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Azathioprine; Organ transplant patients; Skin cancer; UV light

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ARTICLE; CANCER INHIBITION; CANCER RISK; CANCER SUSCEPTIBILITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; GRAFT SURVIVAL; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RISK ASSESSMENT; RISK FACTOR; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; SURVIVAL TIME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET C RADIATION; ULTRAVIOLET RADIATION;

AZATHIOPRINE; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RISK FACTORS; SKIN NEOPLASMS; TACROLIMUS; ULTRAVIOLET RAYS;

EID: 34047100377     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl762     Document Type: Article

References (24)

1. Hampton T. Skin cancer's ranks rise: Immunosuppression to blame. JAMA 2005; 294: 1476-1480
2. Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612
3. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 1741-1751
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-1691
5. Veness MJ, Quinn DI, Ong CS et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: The Australian experience. Cancer 1999; 85: 1758-1764
6. Kasiske BL, Snyder JJ, Gilbertson DT et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913
7. Sheil AG, Disney AP, Mathew TH et al. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-1384
8. Kullavanijaya P, Kim HW. Photoprotection. J Am Acad Dermatol 2005; 52: 937-958
9. Ramsay HM, Fryer AA, Reece S et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36: 167-176
10. Ulrich C, Schmook T, Sachse MM et al. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg 2004; 30: 622-627
11. Hojo M, Morimoto T, Maluccio M et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 185: 9-11
12. Servilla KS, Burnham DK, Daynes RA et al. Ability of cyclosporine to promote the growth of transplanted ultraviolet radiation-induced tumors in mice. Transplantation 1987; 44: 291-295
13. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and Skin Cancer in Transplant Patients: Focus on Rapamycin. Dermatol Surg 2004; 30: 628-633
14. Hiesse C, Larue JR, Kriaa F et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: Single-center analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27: 2450-2451
15. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-186
16. Fortina AB, Caforio AL, Piaserico S et al. Skin cancer in heart transplant recipients: Frequency and risk factor analysis. J Heart Lung Transplant 2000; 19: 249-255
17. Jonas S, Rayes N, Neumann U et al. De novo malignancies after liver transplantation using tacrolimus-based protocols of cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or anithymocyte globulin. Cancer 1997; 80: 1141-1150
18. O'Donovan P, Perrett CM, Zhang X et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874
19. Young AR, Sheehan JM, Chadwick CA et al. Protection by ultraviolet A and B sunscreens against in situ dipyrimidine photolesions in human epidermis is comparable to protection against sunburn. J Invest Dermatol 2000; 115: 37
20. Robson RA, Opelz G, Cecka JM et al. Risk of PTLD and other malignancies in renal transplant patients treated with MMF: A prospective observational cohort study. Am J Transplant 2003; 3 [Suppl 5]: 187
21. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic. Curr Opin Invest Drugs 2002; 3: 295-304
22. Yarosh DB, Boumakis S, Brown AB et al. Measurement of UVB-Induced DNA damage and its consequence in models of immunosuppression. Methods 2002; 28: 55-62
23. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135
24. Kauffman HM, Cherikh WS, Cheng Y et al. OPTN/UNOS Data Shows Significant Difference in Cancer Incidence Rates in Transplant Recipients Based Upon Immunosuppression Regimen 26.October 2005 http://www.unos.org/news/ newsDetail.asp?id=497